DDrare: Database of Drug Development for Rare Diseases

Searched query = "Pemphigus"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = ALXN1830; ARGX-113; Acetaminophen; Acetaminophen/paracetamol; Acetate; Antihistamine (cetirizine or equivalent); Azathioprine; CELLCEPT®; CORTANCYL 20 mg; Carboxymethylcellulose; CellCept 500 mg comprimidos recubiertos; CellCept®500 mg comprimidos; Cellcept® in autoimmune bullous dermatoses; Cellulose; Cetirizine; Cohort 1: 1.0 x 10^8 PolyTregs; Cohort 2: 2.5x10^8 PolyTregs; Combination of Protein A Immunoadsorption, Rituximab, Dexamethasone plus Azathioprine; Cortancyl; Corticosteroids'therapy; Cotton; Cyclophosphamide; DSG3-CAART; Dapsone; Dermoval; Device: Carboxymethylcellulose with ionic silver (Aquacel Ag); Device: Cellulose acetate with petrolatum; Device: Cotton gauze with petrolatum; Device: Nanocrystalline silver (Acticoat); Dexamethasone; Dexamethasone (50mg 1dd6, 3 consecutive days/month); Dexamethasone 0.5mg/5ml solution; Dexamethasone 0.5mg/5ml solution in Mucolox™; EFGARTIGIMOD ALFA; Efgartigimod; Efgartigimod PH20 SC; Efgartigimod alfa; Enbrel (Etanercept); Etanercept; Filgrastim; GLYCINE; GSK1841157; General Corticotherapy; Glycine; Hematopoietic stem cell transplantation; Human interleukin-2; INCB050465; INCB050465 0.3 mg; INCB050465 0.3mg; INCB050465 1.0 mg; INCB050465 1.0mg; INCB050465 2.5mg; INCB050465 HYDROCHLORIDE; INTERLEUKIN-2; IVIg; Ianalumab; Imatinib; Infliximab; Intratect; Intratect 5%; Intravenous immunoglobulin; KC706; MABTHERA; MABTHERA®; MMF; MTX; MabThera; Mabthera; Mabthéra; Mathéra; Methotrexate; Methylprednisolone; Micofenolato mofetilo; Mycophenolate; Mycophenolate Mofetil; Mycophenolate Mofetil (MMF) 3 g/Day; Mycophenolate Mofetil 2 g/Day; Mycophenolate mofetil; OFATUMUMAB; ONO-4059; Ofatumumab; Other: Autologous Platelet rich plasma; Other: IVIg; PI-0824; PREDNISONE; PRN1008; PRN1008 (Rilzabrutinib); PRN1008 Freebase; PRN1008 Oral Tablet; Paracetamol; Parsaclisib; Petrolatum; Prednisolone; Prednisone; Prednisone/Prednisolone; RITUXIMAB; RO0452294/V02; RO1061443/F02; Rapamycin; Recombinant human interleukin-2 (rhIL-2); Rituximab; Rituximab (MABTHERA® or RITUXAN®).; Rituximab and Cyclophosphamide IV; Silver; Sirolimus; Sirolimus (formerly known as Rapamycin); TPM203; Tirabrutinib; Triamcinolone; Triamcinolone Acetonide; VAY736; WATER FOR INJECTION; Water; [NA]

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00063752 (ClinicalTrials.gov)	July 2003	3/7/2003	Safety Study of PI-0824 to Treat Pemphigus Vulgaris	An Open-Label, Dose-Escalation, Phase I Clinical Study to Assess the Safety of PI-0824 in Patient With Pemphigus Vulgaris Requiring Daily Corticosteroid Therapy	Pemphigus Vulgaris	Drug: PI-0824	Peptimmune	NULL	Completed	18 Years	N/A	Both	15	Phase 1	United States

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT00063752
(ClinicalTrials.gov)

July 2003

3/7/2003

Safety Study of PI-0824 to Treat Pemphigus Vulgaris

An Open-Label, Dose-Escalation, Phase I Clinical Study to Assess the Safety of PI-0824 in Patient With Pemphigus Vulgaris Requiring Daily Corticosteroid Therapy

Pemphigus Vulgaris

Drug: PI-0824

Peptimmune

NULL

Completed

18 Years

N/A

Both

Phase 1

United States